Johnson & Johnson (J&J) has acquired Halda Therapeutics for $3.05bn in cash, bringing the RIPTAC platform to J&J’s oncology portfolio. The deal includes a once-daily oral therapy for prostate cancer and early-stage candidates for other tumour types. Earnings dilution is expected in 2025 and 2026, impacting adjusted earnings per share by $0.20.

J&J’s innovative medicine chairman and EVP Jennifer Taubert expressed excitement over the strategic milestone, aiming to redefine cancer treatment with transformative medicines. Executive VP John Reed highlighted the focus on advancing the pipeline of novel product candidates and leveraging the RIPTAC platform for oncology and beyond. The acquisition was finalized in November 2025.

The acquisition of Halda Therapeutics marks a significant step for J&J in expanding its oncology portfolio. The company is focused on harnessing breakthrough science and transformative medicines to eliminate cancer. The addition of the RIPTAC platform and promising pipeline of product candidates demonstrate J&J’s commitment to innovation in cancer treatment.

Read more at Yahoo Finance: Johnson & Johnson acquires Halda Therapeutics for $3.05bn